Bisamide sarcomere activating compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-11780826-B2
Application number	US-202217672594-A
Country	US
Kind code	B2
Filing date	Feb 15, 2022
Priority date	Sep 13, 2017
Publication date	Oct 10, 2023
Grant date	Oct 10, 2023

Abstract

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

First claim

What is claimed:

1. A compound of formula:

2. A composition comprising the compound of claim 1 .

3. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

4. A method of treating heart disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

5. The method of claim 4 , wherein the heart disease is selected from the group consisting of: heart failure with reduced ejection fraction, dilated cardiomyopathy, postpartum cardiomyopathy, idiopathic cardiomyopathy, pediatric HFrEF, chemotherapy-induced heart failure, heart failure associated with muscular dystrophy, bi-ventricular HFrEF, HFrEF with pulmonary hypertension, heart failure with preserved ejection fraction (HFpEF) with right ventricular dysfunction, pulmonary hypertension with right ventricular dysfunction, scleroderma with pulmonary hypertension, right ventricular dysfunction, Chagas disease, and myocarditis.

6. The method of claim 5 , wherein the heart disease is heart failure with reduced ejection fraction.

7. The method of claim 5 , wherein the heart disease is pediatric HFrEF.

8. The method of claim 5 , wherein the heart disease is bi-ventricular HFrEF.

9. The method of claim 5 , wherein the heart disease is HFrEF with pulmonary hypertension.

10. The method of claim 5 , wherein the heart disease is heart failure with preserved ejection fraction (HFpEF) with right ventricular dysfunction.

11. The method of claim 5 , wherein the heart disease is myocarditis.

12. A method of treating heart disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 3 .

13. The method of claim 12 , wherein the heart disease is selected from the group consisting of: heart failure with reduced ejection fraction, dilated cardiomyopathy, postpartum cardiomyopathy, idiopathic cardiomyopathy, pediatric HFrEF, chemotherapy-induced heart failure, heart failure associated with muscular dystrophy, bi-ventricular HFrEF, HFrEF with pulmonary hypertension, heart failure with preserved ejection fraction (HFpEF) with right ventricular dysfunction, pulmonary hypertension with right ventricular dysfunction, scleroderma with pulmonary hypertension, right ventricular dysfunction, Chagas disease, and myocarditis.

14. The method of claim 13 , wherein the heart disease is heart failure with reduced ejection fraction.

15. The method of claim 13 , wherein the heart disease is pediatric HFrEF.

16. The method of claim 13 , wherein the heart disease is bi-ventricular HFrEF.

17. The method of claim 13 , wherein the heart disease is HFrEF with pulmonary hypertension.

18. The method of claim 13 , wherein the heart disease is heart failure with preserved ejection fraction (HFpEF) with right ventricular dysfunction.

19. The method of claim 13 , wherein the heart disease is myocarditis.

Assignees

• Amgen Inc
• Cytokinetics Inc

Inventors

• Ashcraft Luke
• Boezio Alessandro
• Butler John
• Chandra Aroop
• Chuang Chihyuan
• Collibee Scott E
• Debenedetto Mikkel
• Dimassa Vincent
• Graceffa Russell
• Malinowski Justin
• Moebius David
• Morgan Bradley P
• Payette Joshua
• Romero Antonio
• St Jean Jr David
• Vargas Richard
• Yeoman John
• Zhang Hanmo
• Cheng Alan
• Gonzalez Lopez De Turiso Felix
• Johnson Michael Garrett

Classifications

• C07D403/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• A61P9/00 Primary

  Drugs for disorders of the cardiovascular system · CPC title

• C07D207/16

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D209/02

  condensed with one carbocyclic ring · CPC title

• C07D209/52

  condensed with a ring other than six-membered · CPC title